<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingJeffrey A. Engelman, Pasi A. Jänne, Kreshnik Zejnullahu et al.|Science|2007Cited by 4.5k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Ming‐Huang Chen, Makoto Ueno et al.|The Lancet|2023Cited by 1k
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialFlorian Lordick, Markus Moehler, Hyun Cheol Chung et al.|The Lancet Oncology|2013Cited by 838
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo‐Youn Oh, Juan W. Valle, Aiwu Ruth He et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 245
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic CancerHedy L. Kindler, Talia Golan, Pascal Hammel et al.|Journal of Clinical Oncology|2022Cited by 224